Related Experiment Video
Updated: Sep 29, 2025

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
Published on: July 7, 2023
Unsupervised characterization of Major Depressive Disorder medication treatment pathways
Barrett Jones1, Colin G Walsh1,2,3
1Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Abstract:
Learning health systems have the ability to systematically evaluate treatments and treatment pathways. Characterization of treatment pathways can enhance a health system's ability to perform systematic evaluation to improve care quality. In this study we use a Long-Short Term Memory (LSTM) autoencoder model to systematically characterize treatment pathways in a prevalent phenotype-Major Depressive Disorder (MDD). LSTM autoencoder models generate representations of medication treatment pathways that account for temporality and complex interactions. Patients with similar pathways are grouped with K-means clustering. Clusters are characterized by analysis of medication utilization sequences and trends, as well as clinical features, such as demographics, outcomes and comorbidities. Cluster characterization identifies endotypes of MDD including acute MDD, moderate-chronic MDD and severe-chronic, but managed MDD.
More Related Videos
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Overview
Drug Therapy
Antianxiety Medications
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Psychosis: Goals of Pharmacotherapy
Depressive Disorders: MDD and Dysthymia

